Jasper Carlsen

Dr. Jasper Carlsen


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SMSigne Mosegaard
Signe Mosegaard
GDGraziana Dipace
Graziana Dipace
Peter BrossPeter Bross
Peter Bross
JCJasper Carlsen
Jasper Carlsen
NGNiels Gregersen
Niels Gregersen
RORikke Katrine Jentoft Olsen
Rikke Katrine Jentoft Olsen
As an essential vitamin, the role of riboflavin in human diet and health is increasingly being highlighted. Insufficient dietary intake of riboflavin is often reported in nutritional surveys and population studies, even in non-developing countries with abundant sources of riboflavin-rich dietary products. A latent subclinical riboflavin deficiency can result in a significant clinical phenotype when combined with inborn genetic disturbances or environmental and physiological factors like infections, exercise, diet, aging and pregnancy. Riboflavin, and more importantly its derivatives, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), play a crucial role in essential cellular processes including mitochondrial energy metabolism, stress responses, vitamin and cofactor biogenesis, where they function as cofactors to ensure the catalytic activity and folding/stability of flavoenzymes. Numerous inborn errors of flavin metabolism and flavoenzyme function have been described, and supplementation with riboflavin has in many cases been shown to be lifesaving or to mitigate symptoms. This review discusses the environmental, physiological and genetic factors that affect cellular riboflavin status. We describe the crucial role of riboflavin for general human health, and the clear benefits of riboflavin treatment in patients with inborn errors of metabolism.

1 January 2019 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
NSNavid Sahebekhtiari
Navid Sahebekhtiari
PFPaula Fernandez-Guerra
Paula Fernandez-Guerra
ZNZahra Nochi
Zahra Nochi
JCJasper Carlsen
Jasper Carlsen
Peter BrossPeter Bross
Peter Bross
JPJohan Palmfeldt
Johan Palmfeldt

25 April 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
JCJasper Carlsen
Jasper Carlsen
SFSilvia Fossati
Silvia Fossati
LØLeif Østergaard
Leif Østergaard
EGEugenio Gutiérrez‐Jiménez
Eugenio Gutiérrez‐Jiménez
JPJohan Palmfeldt
Johan Palmfeldt
BACKGROUND: Cerebral amyloid angiopathy (CAA) is a hallmark of Alzheimer's disease (AD), linked to adverse effects of emerging AD treatments. We explored the molecular effects of CAA in mouse brain and evaluated how these could be prevented by two repurposed United States Food and Drug Administration (FDA) approved treatments.METHODS: Brain proteomics was performed on the Tg‐SwDI genetic mouse model carrying disease causing mutations and developing AD characteristic cognitive deficits and severe CAA. Cortical and hippocampal tissues from presymptomatic male and female mice were studied.RESULTS: We identify a core of dysregulated proteins across studies, including established markers of AD as well as proteins indicative of astrogliosis and negative regulators of synaptic stability and function. Two FDA approved, repurposed carbonic anhydrase inhibitors (CAIs), acetazolamide and methazolamide, were effective in preventing these molecular adaptations.DISCUSSION: The two drugs broadly prevent proteome adaptations to the detrimental genotype and retain glutamatergic synapse proteins significantly closer to wild‐type levels.Highlights: The brain proteome changes of mice with CAA are mapped. Cortical and hippocampal tissues from presymptomatic male and female mice are studied. Markers of AD, astrogliosis, and synaptic stability are dysregulated. Two CAI are effective in preventing these protein changes.

2 February 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CCCagla Cömert
Cagla Cömert
KKKasper Kjær-Sørensen
Kasper Kjær-Sørensen
JHJakob Hansen
Jakob Hansen
JCJasper Carlsen
Jasper Carlsen
JJJesper Just
Jesper Just
Peter BrossPeter Bross
Peter Bross
Mitochondrial proteostasis is critical for cellular function and survival. HSP60 is a molecular chaperone that interacts with more than 260 mitochondrial matrix proteins to assist in their folding and few genetic variants of HSP60 are compatible with life. The few reported human patients with HSP60 variants show phenotypes of neurodevelopmental delay associated with brain hypomyelination. It is currently unknown how deficiency of the HSP60 links to hypomyelination. Here, we studied the onset and progression of HSP60 deficiency in: (1) a HSP60 mutation-inducible cell system, (2) skin fibroblasts from patients with disease-associated HSP60 variants, and (3) zebrafish HSP60 knockout larvae. Collectively, we show how HSP60 deficiency leads to pervasive dysfunctions: (1) downregulated mitochondrial matrix proteome, (2) transcriptional activation of cytosolic stress responses, (3) and lipid accumulation with dysregulated cholesterol biosynthesis. In zebrafish larvae HSP60 deficiency induced early developmental abnormalities. Our comprehensive data identifies HSP60 as a master regulator of mitochondrial proteostasis and suggests a pivotal effect of HSP60 dysfunction on myelination through dysregulation of cholesterol biosynthesis. Highlights HSP60 deficiency disrupts mitochondrial matrix proteins activating stress responses Disrupted matrix proteome impairs catabolism causing acetyl-CoA shortage HSP60 deficiency dysregulates cytosolic cholesterol synthesis Hsp60 deficiency causes developmental abnormalities in zebrafish larvae Dysregulated cholesterol synthesis links HSP60 deficiency to hypomyelination